Literature DB >> 19307972

No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients.

Luca La Colla1, Andrea Albertin, Giorgio La Colla, Valerio Ceriani, Tiziana Lodi, Andrea Porta, Giorgio Aldegheri, Alberto Mangano, Ilias Khairallah, Isabella Fermo.   

Abstract

BACKGROUND AND
OBJECTIVE: The purpose of this prospective, randomized, double-blind study was to determine the predictive performance of target-controlled infusions of propofol in morbidly obese patients using the 'Marsh' pharmacokinetic parameter set.
METHODS: Twenty-four patients (ASA II or III, age 25-62 years, BMI 35.5-61.7) were randomly allocated to receive propofol target-controlled infusion based on a weight adjustment formula (group adjusted) or without adjustment [group total body weight (TBW)]. Anaesthesia was induced by a propofol-targeted concentration of 6 microg ml that was subsequently adapted to maintain stable bispectral index values ranging between 40 and 50. Arterial blood samples were collected before the start of the infusion and every 15 min thereafter to determine the predictive performances.
RESULTS: There were no statistically significant differences between the groups with regard to performance errors, divergence and wobble. Results are presented as median (interquartiles). Median performance error and median absolute performance error were -31.7 (-35.9, -19.4) and 31.7% (20.2, 35.9) for group adjusted and -16.3 (-26.3, 2.2) and 20.6% (14.8, 26.9) for group TBW, respectively. Wobble median value was 7.4% (3.8, 8.4) for group adjusted and 8.2% (7.0, 9.6) for group TBW. As for wobble and divergence, no statistically significant differences were found between groups.
CONCLUSION: Weight adjustment causes a clinically unacceptable performance bias, which is not corrected when TBW is used as an input to the 'Marsh' model. It is, therefore, advisable to administer propofol to morbidly obese patients by titration to targeted processed-EEG values.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307972     DOI: 10.1097/EJA.0b013e328326f7d0

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

1.  Obesity and allometric scaling of pharmacokinetics.

Authors:  Douglas J Eleveld; Johannes H Proost; Anthony R Absalom; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

2.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

3.  Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions.

Authors:  Johan Francois Coetzee
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

4.  Anesthetic Pharmacology and the Morbidly Obese Patient.

Authors:  Jerry Ingrande; Hendrikus Jm Lemmens
Journal:  Curr Anesthesiol Rep       Date:  2012-12-13

5.  The determinants of propofol induction time in anesthesia.

Authors:  Yushi U Adachi; Maiko Satomoto; Hideyuki Higuchi; Kazuhiko Watanabe
Journal:  Korean J Anesthesiol       Date:  2013-08-27

6.  Society of Anesthesia and Sleep Medicine Guideline on Intraoperative Management of Adult Patients With Obstructive Sleep Apnea.

Authors:  Stavros G Memtsoudis; Crispiana Cozowicz; Mahesh Nagappa; Jean Wong; Girish P Joshi; David T Wong; Anthony G Doufas; Meltem Yilmaz; Mark H Stein; Megan L Krajewski; Mandeep Singh; Lukas Pichler; Satya Krishna Ramachandran; Frances Chung
Journal:  Anesth Analg       Date:  2018-10       Impact factor: 5.108

7.  Evaluation of propofol anesthesia in morbidly obese children and adolescents.

Authors:  Vidya Chidambaran; Senthilkumar Sadhasivam; Jeroen Diepstraten; Hope Esslinger; Shareen Cox; Beverly M Schnell; Paul Samuels; Thomas Inge; Alexander A Vinks; Catherijne A Knibbe
Journal:  BMC Anesthesiol       Date:  2013-04-21       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.